Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States
Open Access
- 1 June 2022
- journal article
- research article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (3) , 949-957
Abstract
Original Article Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States Jessica A. Davis, Zhanglin Lin Cui, Madiha Ghias, Xiaohong Li, Robert Goodloe, Chunxiao Wang, Astra M. Liepa, Lisa M. HessKeywords
This publication has 12 references indexed in Scilit:
- Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaCancer Control, 2019
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology, 2018
- Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.Gastric Cancer, 2018
- Advanced gastric cancer: Current treatment landscape and future perspectivesWorld Journal of Gastroenterology, 2016
- Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims dataGastric Cancer, 2015
- Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims DatabaseJournal of Gastric Cancer, 2015
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 2014
- Hospitals, Market Share, and ConsolidationJAMA, 2013
- Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity2011